IMP4297 DDI (Drug-Drug Interaction)Trial in Healthy Male Volunteers

Phase 1 Completed 32 enrolled Impact Therapeutics, Inc.

Non-randomizedParallel-groupOpen-labelOther

Summary

A Phase I, Open-label, Fixed-Sequence Study to Evaluate the Effect of Multiple-dose Itraconazole or Rifampicin Capsules on the Single-dose PK Profiles of IMP4297 Capsules in Healthy Subjects

Timeline

Start: 2020-11-02
Primary completion: 2021-03-08
Completion: 2021-05-27

Publications

Hu X, Hsieh CY, Zhang Y, Liu W, Xu S, Cai SX, Liu L, Zhang M, Shi H, Zhang H, Liu P, Li X, Xu P. Effect of a strong CYP3A4 inhibitor and inducer on the pharmacokinetics of senaparib (IMP4297) in healthy volunteers: A drug-drug interaction study. Br J Clin Pharmacol. 2023 Jun;89(6):1767-1779. doi: 10.1111/bcp.15624. Epub 2023 Jan 3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	IMP4297	Unknown	40 mg	Oral
Subject	IMP4297	Unknown	100 mg	Oral
Subject	Itraconazole	Small molecule	200 mg	Oral
Subject	Rifampin	Small molecule	600 mg	Oral

IMP4297 DDI (Drug-Drug Interaction)Trial in Healthy Male Volunteers

Summary

Timeline

Publications

Drugs

Indications